The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).
 
Eddy Saad
Research Funding - Genentech/Roche (Inst); Oncohost
 
Nourhan El Ahmar
No Relationships to Disclose
 
Berkay Simsek
No Relationships to Disclose
 
Opeyemi Jegede
Research Funding - Bristol Myers Squibb Foundation
 
Sayed Matar
No Relationships to Disclose
 
Razan Mohanna
No Relationships to Disclose
 
Emre Yekeduz
No Relationships to Disclose
 
David McDermott
Consulting or Advisory Role - alkermes; Arcus Biosciences; Bristol-Myers Squibb; Cullinan Oncology; Eisai; EMD Serono; exelixis; Iovance Biotherapeutics; Lilly; Merck; Pfizer; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Merck; Pfizer; Seagen; Signatera; Synthekine
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Jeffrey Sosman
Honoraria - Apexigen; Aveo; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Iovance Biotherapeutics; Jazz Pharmaceuticals
Research Funding - Werewolf Pharma (Inst)
 
Naomi Haas
Consulting or Advisory Role - Eisai; Merck Sharp & Dohme
 
Michael Hurwitz
Employment - Arvinas (I); Faeth Therapeutics (I); Gamida Cell (I); Pfizer (I)
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Affini-T Therapeutics; Bristol-Myers Squibb/Celgene; crispr therapeutics; Exelixis; Janssen; Nektar; pliant; Regeneron; TScan Therapeutics
Research Funding - Achilles Therapeutics; Achilles Therapeutics; Apexigen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Endocyte; Endocyte; Genentech; Genmab; Innocrin Pharma; Iovance Biotherapeutics; Lilly; Lyell Immunopharma; Lyell Immunopharma; Merck; Nektar; Novartis; Novartis; Pfizer; Progenics; Sanofi/Aventis; Seagen; Synthekine; Torque; Unum Therapeutics; Xilio Therapeutics
 
Hans Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Aveo (Inst); Bristol-Myers Squibb (Inst); Hibercell (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Eliezer Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Genomic Life; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Genomic Life; Illumina; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Toni Choueiri
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; bicycle; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Michael Atkins
Leadership - Werewolf Therapeutics
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - 23AndMe; Abbvie; Agenus; AstraZeneca; Aveo; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Innovent Biologics; IO Biotech; Jazz Pharmaceuticals; Merck; Novartis; Oncorena; Pfizer; Pliant; Pyxis; Replimune; Sanofi; Simcha Therapeutics; Syncona; Werewolf Pharma
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - BMS Canada; BMS Sweden
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; crispr therapeutics; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI
 
David Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Dedham Group; Defined Health; DLA Piper; Eisai; Elephas Bio; Exelixis; Insight Strategy; Link Cell Therapies; Merck; Neomorph; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Scholar Rock; Scholar Rock; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb